pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1303 |
Genomic Coordinates | chr5: 154685776 - 154685861 |
Synonyms | MIRN1303, hsa-mir-1303, MIR1303 |
Description | Homo sapiens miR-1303 stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1303 | ||||||||||||||||||||||||||||||||||||||||||
Sequence | 52| UUUAGAGACGGGGUCUUGCUCU |73 | ||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | PLA2G16 | ||||||||||||||||||||
Synonyms | AdPLA, H-REV107, H-REV107-1, HRASLS3, HREV107, HREV107-1, HREV107-3, HRSL3 | ||||||||||||||||||||
Description | phospholipase A2 group XVI | ||||||||||||||||||||
Transcript | NM_001128203 | ||||||||||||||||||||
Other Transcripts | NM_007069 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on PLA2G16 | |||||||||||||||||||||
3'UTR of PLA2G16 (miRNA target sites are highlighted) |
>PLA2G16|NM_001128203|3'UTR 1 CTGAAAAAGACTGTCCTGTCAGCGATGACTTTATACATCAAGGGGGTCTTGTTTTGCTAGAGAGTTTGGGGTTTGGTTTG 81 TGGATTTCATTGTGATTTATAATAAGGCTTATTTTCACAGAATAAAATAAAGCAAAACGAGGGAGGATTTTATTGGGGGA 161 AGTGCAGCAAGAACTGCCTGGTGTGAAGTCTGTTCAGGGAACAGCCGGGCTGTCTTCCTGGTCAGGGATTGTCTTTCACT 241 TTCTTTTTGCGTGCTGTGTTCTTTGCATTGCAGGAGGCAGAGTCCAGCTCCAGTTATCTCAAGTAGAGGGCGTTTCTGGT 321 CGTCAGGATACATGCGGGGCGGAAGGGAGACAGAAAGACATAATACACAAGAACAGAAAGCAGCAGACAGCCAGGACCCT 401 TGGCCCGGAACTAGATCTAGGATGGCCTCTGAGACTCAGCAGCTGGAGTCTGTAGATGTTCAGCTGAGTTGAAAAAAAAA 481 AAG Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545215. RNA binding protein: AGO4. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084065. RNA binding protein: AGO2. Condition:CLIP_emetine_AbnovaAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Cardiac Tissues |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM2202476. RNA binding protein: AGO2. Condition:S1_LV_54yo_Male_AGO2_bound_RNA
HITS-CLIP data was present in GSM2202481. RNA binding protein: AGO2. Condition:S6_LV_61yo_Male_AGO2_bound_RNA
... - Spengler RM; Zhang X; Cheng C; McLendon JM; et al., 2016, Nucleic acids research. |
Article |
Elucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIP.
- Spengler RM; Zhang X; Cheng C; McLendon JM; et al.- Nucleic acids research, 2016
MicroRNAs (miRs) have emerged as key biological effectors in human health and disease. These small noncoding RNAs are incorporated into Argonaute (Ago) proteins, where they direct post-transcriptional gene silencing via base-pairing with target transcripts. Although miRs have become intriguing biological entities and attractive therapeutic targets, the translational impacts of miR research remain limited by a paucity of empirical miR targeting data, particularly in human primary tissues. Here, to improve our understanding of the diverse roles miRs play in cardiovascular function and disease, we applied high-throughput methods to globally profile miR:target interactions in human heart tissues. We deciphered Ago2:RNA interactions using crosslinking immunoprecipitation coupled with high-throughput sequencing (HITS-CLIP) to generate the first transcriptome-wide map of miR targeting events in human myocardium, detecting 4000 cardiac Ago2 binding sites across >2200 target transcripts. Our initial exploration of this interactome revealed an abundance of miR target sites in gene coding regions, including several sites pointing to new miR-29 functions in regulating cardiomyocyte calcium, growth and metabolism. Also, we uncovered several clinically-relevant interactions involving common genetic variants that alter miR targeting events in cardiomyopathy-associated genes. Overall, these data provide a critical resource for bolstering translational miR research in heart, and likely beyond.
LinkOut: [PMID: 27418678]
|
CLIP-seq Support 1 for dataset GSM1084065 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_emetine_AbnovaAb |
Location of target site | ENST00000323646.5 | 3UTR | AAAAAAUACACACACACAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM545215 | |
---|---|
Method / RBP | PAR-CLIP / AGO4 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000323646.5 | 3UTR | AAAAAAAUACACACACACACACACAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
186 hsa-miR-1303 Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT035871 | SOAT1 | sterol O-acyltransferase 1 | ![]() |
1 | 1 | |||||||
MIRT035872 | FHOD3 | formin homology 2 domain containing 3 | ![]() |
1 | 1 | |||||||
MIRT035873 | RPL7A | ribosomal protein L7a | ![]() |
1 | 1 | |||||||
MIRT035874 | NCAPD2 | non-SMC condensin I complex subunit D2 | ![]() |
1 | 1 | |||||||
MIRT035875 | RPS8 | ribosomal protein S8 | ![]() |
1 | 1 | |||||||
MIRT035876 | AHNAK | AHNAK nucleoprotein | ![]() |
1 | 1 | |||||||
MIRT035877 | ACTB | actin beta | ![]() |
1 | 1 | |||||||
MIRT035878 | DEF8 | differentially expressed in FDCP 8 homolog | ![]() |
1 | 1 | |||||||
MIRT035879 | MET | MET proto-oncogene, receptor tyrosine kinase | ![]() |
1 | 1 | |||||||
MIRT035880 | MED13 | mediator complex subunit 13 | ![]() |
1 | 1 | |||||||
MIRT035881 | FAT3 | FAT atypical cadherin 3 | ![]() |
1 | 1 | |||||||
MIRT035882 | HUWE1 | HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase | ![]() |
1 | 1 | |||||||
MIRT035883 | RPS16 | ribosomal protein S16 | ![]() |
1 | 1 | |||||||
MIRT035884 | CDK6 | cyclin dependent kinase 6 | ![]() |
1 | 1 | |||||||
MIRT035885 | GEMIN5 | gem nuclear organelle associated protein 5 | ![]() |
1 | 1 | |||||||
MIRT035886 | PITRM1 | pitrilysin metallopeptidase 1 | ![]() |
1 | 1 | |||||||
MIRT035887 | PRRC2A | proline rich coiled-coil 2A | ![]() |
1 | 1 | |||||||
MIRT035888 | KIAA0226 | RUN and cysteine rich domain containing beclin 1 interacting protein | ![]() |
1 | 1 | |||||||
MIRT035889 | MLLT6 | MLLT6, PHD finger containing | ![]() |
1 | 1 | |||||||
MIRT035890 | EIF3I | eukaryotic translation initiation factor 3 subunit I | ![]() |
1 | 1 | |||||||
MIRT035891 | FASN | fatty acid synthase | ![]() |
1 | 1 | |||||||
MIRT035892 | LEPREL4 | prolyl 3-hydroxylase family member 4 (non-enzymatic) | ![]() |
1 | 1 | |||||||
MIRT035893 | HSCB | HscB mitochondrial iron-sulfur cluster cochaperone | ![]() |
1 | 1 | |||||||
MIRT035894 | PSME4 | proteasome activator subunit 4 | ![]() |
1 | 1 | |||||||
MIRT035895 | FRS2 | fibroblast growth factor receptor substrate 2 | ![]() |
1 | 1 | |||||||
MIRT035896 | ZNF264 | zinc finger protein 264 | ![]() |
1 | 1 | |||||||
MIRT035897 | HYLS1 | HYLS1, centriolar and ciliogenesis associated | ![]() |
1 | 1 | |||||||
MIRT035898 | USP54 | ubiquitin specific peptidase 54 | ![]() |
1 | 1 | |||||||
MIRT035899 | L1TD1 | LINE1 type transposase domain containing 1 | ![]() |
1 | 1 | |||||||
MIRT035900 | OR51E2 | olfactory receptor family 51 subfamily E member 2 | ![]() |
1 | 1 | |||||||
MIRT053762 | CLDN18 | claudin 18 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT060730 | RPS3 | ribosomal protein S3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT083986 | RAB22A | RAB22A, member RAS oncogene family | ![]() |
![]() |
2 | 2 | ||||||
MIRT098550 | TBPL1 | TATA-box binding protein like 1 | ![]() |
![]() |
2 | 6 | ||||||
MIRT134983 | TWF1 | twinfilin actin binding protein 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT136956 | FNDC3A | fibronectin type III domain containing 3A | ![]() |
![]() |
2 | 2 | ||||||
MIRT222065 | PURB | purine rich element binding protein B | ![]() |
![]() |
2 | 2 | ||||||
MIRT239574 | UBN2 | ubinuclein 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT261820 | BUB3 | BUB3, mitotic checkpoint protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT264698 | C11ORF57 | chromosome 11 open reading frame 57 | ![]() |
![]() |
2 | 4 | ||||||
MIRT308476 | GXYLT2 | glucoside xylosyltransferase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT377481 | NDUFB5 | NADH:ubiquinone oxidoreductase subunit B5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT442304 | NEU3 | neuraminidase 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446083 | SLC30A10 | solute carrier family 30 member 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449606 | PRPF4 | pre-mRNA processing factor 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT453767 | NUCB1 | nucleobindin 1 | ![]() |
![]() |
2 | 10 | ||||||
MIRT455603 | SRSF3 | serine and arginine rich splicing factor 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT455913 | KIF2C | kinesin family member 2C | ![]() |
![]() |
2 | 2 | ||||||
MIRT460091 | ZYG11B | zyg-11 family member B, cell cycle regulator | ![]() |
![]() |
2 | 4 | ||||||
MIRT460866 | UBE2S | ubiquitin conjugating enzyme E2 S | ![]() |
![]() |
2 | 2 | ||||||
MIRT461339 | NUP133 | nucleoporin 133 | ![]() |
![]() |
2 | 2 | ||||||
MIRT463769 | YOD1 | YOD1 deubiquitinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT466368 | THAP1 | THAP domain containing 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT467168 | SPTY2D1 | SPT2 chromatin protein domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT468703 | SDHD | succinate dehydrogenase complex subunit D | ![]() |
![]() |
2 | 2 | ||||||
MIRT469122 | RNF126 | ring finger protein 126 | ![]() |
![]() |
2 | 2 | ||||||
MIRT472426 | NCBP2 | nuclear cap binding protein subunit 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT479420 | CDKN1B | cyclin dependent kinase inhibitor 1B | ![]() |
![]() |
2 | 8 | ||||||
MIRT484260 | FAM177A1 | family with sequence similarity 177 member A1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT485468 | IL6ST | interleukin 6 signal transducer | ![]() |
![]() |
2 | 10 | ||||||
MIRT490237 | H2AFZ | H2A histone family member Z | ![]() |
![]() |
2 | 6 | ||||||
MIRT491002 | ATF7IP | activating transcription factor 7 interacting protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT492127 | SUMO2 | small ubiquitin-like modifier 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT499169 | RBPJL | recombination signal binding protein for immunoglobulin kappa J region like | ![]() |
![]() |
2 | 2 | ||||||
MIRT499825 | PCSK9 | proprotein convertase subtilisin/kexin type 9 | ![]() |
![]() |
2 | 8 | ||||||
MIRT501794 | NRAS | NRAS proto-oncogene, GTPase | ![]() |
![]() |
2 | 2 | ||||||
MIRT503441 | GINS4 | GINS complex subunit 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT503688 | MAVS | mitochondrial antiviral signaling protein | ![]() |
![]() |
2 | 5 | ||||||
MIRT506926 | IGDCC4 | immunoglobulin superfamily DCC subclass member 4 | ![]() |
![]() |
2 | 6 | ||||||
MIRT511430 | HOXA10 | homeobox A10 | ![]() |
![]() |
2 | 6 | ||||||
MIRT512415 | LAYN | layilin | ![]() |
![]() |
2 | 4 | ||||||
MIRT513791 | NIPAL3 | NIPA like domain containing 3 | ![]() |
![]() |
2 | 4 | ||||||
MIRT516163 | NTMT1 | N-terminal Xaa-Pro-Lys N-methyltransferase 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT516513 | PARK2 | parkin RBR E3 ubiquitin protein ligase | ![]() |
![]() |
2 | 2 | ||||||
MIRT516915 | HINFP | histone H4 transcription factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT517102 | NDUFV3 | NADH:ubiquinone oxidoreductase subunit V3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT517350 | NLRP9 | NLR family pyrin domain containing 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT518019 | ABHD15 | abhydrolase domain containing 15 | ![]() |
![]() |
2 | 2 | ||||||
MIRT520945 | SRSF10 | serine and arginine rich splicing factor 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT525250 | RNF213 | ring finger protein 213 | ![]() |
![]() |
2 | 2 | ||||||
MIRT530634 | PPIC | peptidylprolyl isomerase C | ![]() |
![]() |
2 | 4 | ||||||
MIRT530671 | CHRNB1 | cholinergic receptor nicotinic beta 1 subunit | ![]() |
![]() |
2 | 4 | ||||||
MIRT531563 | ILDR1 | immunoglobulin like domain containing receptor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT538205 | CYR61 | cysteine rich angiogenic inducer 61 | ![]() |
![]() |
2 | 2 | ||||||
MIRT538419 | COLEC10 | collectin subfamily member 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT541964 | ZNF485 | zinc finger protein 485 | ![]() |
![]() |
2 | 2 | ||||||
MIRT543088 | KNSTRN | kinetochore localized astrin/SPAG5 binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT543257 | ZNF662 | zinc finger protein 662 | ![]() |
![]() |
2 | 2 | ||||||
MIRT543589 | KIAA1549 | KIAA1549 | ![]() |
![]() |
2 | 2 | ||||||
MIRT543955 | RNF20 | ring finger protein 20 | ![]() |
![]() |
2 | 2 | ||||||
MIRT544043 | C9orf64 | chromosome 9 open reading frame 64 | ![]() |
![]() |
2 | 4 | ||||||
MIRT548064 | GIGYF1 | GRB10 interacting GYF protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT548240 | FBXW7 | F-box and WD repeat domain containing 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT548442 | EIF1AX | eukaryotic translation initiation factor 1A, X-linked | ![]() |
![]() |
2 | 2 | ||||||
MIRT548623 | DAZAP1 | DAZ associated protein 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT548770 | COLEC12 | collectin subfamily member 12 | ![]() |
![]() |
2 | 2 | ||||||
MIRT549506 | HDDC2 | HD domain containing 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT551924 | AKAP8 | A-kinase anchoring protein 8 | ![]() |
![]() |
2 | 4 | ||||||
MIRT555656 | PGRMC1 | progesterone receptor membrane component 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT556286 | MAP3K5 | mitogen-activated protein kinase kinase kinase 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT557012 | HOXD13 | homeobox D13 | ![]() |
![]() |
2 | 4 | ||||||
MIRT563907 | CLSPN | claspin | ![]() |
![]() |
2 | 2 | ||||||
MIRT565527 | SON | SON DNA binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT568000 | COMMD2 | COMM domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT569831 | PLA2G16 | phospholipase A2 group XVI | ![]() |
![]() |
2 | 4 | ||||||
MIRT573905 | PARP1 | poly(ADP-ribose) polymerase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT616589 | KLHL9 | kelch like family member 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617137 | ZNF556 | zinc finger protein 556 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617400 | API5 | apoptosis inhibitor 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT617455 | CCS | copper chaperone for superoxide dismutase | ![]() |
![]() |
2 | 2 | ||||||
MIRT617799 | ZNF793 | zinc finger protein 793 | ![]() |
![]() |
2 | 2 | ||||||
MIRT618190 | MACC1 | MACC1, MET transcriptional regulator | ![]() |
![]() |
2 | 2 | ||||||
MIRT618303 | GNE | glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase | ![]() |
![]() |
2 | 2 | ||||||
MIRT618329 | ZNF813 | zinc finger protein 813 | ![]() |
![]() |
2 | 2 | ||||||
MIRT618820 | PHF20 | PHD finger protein 20 | ![]() |
![]() |
2 | 2 | ||||||
MIRT619153 | PPDPF | pancreatic progenitor cell differentiation and proliferation factor | ![]() |
![]() |
2 | 2 | ||||||
MIRT619530 | ZNF708 | zinc finger protein 708 | ![]() |
![]() |
2 | 2 | ||||||
MIRT619849 | KIR3DX1 | killer cell immunoglobulin like receptor, three Ig domains X1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT620806 | SLC26A2 | solute carrier family 26 member 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT621312 | YIPF4 | Yip1 domain family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT621358 | GUCA1B | guanylate cyclase activator 1B | ![]() |
![]() |
2 | 2 | ||||||
MIRT621366 | ART4 | ADP-ribosyltransferase 4 (Dombrock blood group) | ![]() |
![]() |
2 | 2 | ||||||
MIRT621547 | ZMYM1 | zinc finger MYM-type containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT621883 | TAOK1 | TAO kinase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT622451 | RNF19B | ring finger protein 19B | ![]() |
![]() |
2 | 2 | ||||||
MIRT623404 | KREMEN1 | kringle containing transmembrane protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT623587 | IPO9 | importin 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT623974 | FAM63A | MINDY lysine 48 deubiquitinase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT624086 | DPP8 | dipeptidyl peptidase 8 | ![]() |
![]() |
2 | 2 | ||||||
MIRT624108 | DNAH10OS | dynein axonemal heavy chain 10 opposite strand | ![]() |
![]() |
2 | 2 | ||||||
MIRT632486 | RNF8 | ring finger protein 8 | ![]() |
![]() |
2 | 2 | ||||||
MIRT634057 | PLIN3 | perilipin 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT634657 | GDE1 | glycerophosphodiester phosphodiesterase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT640682 | MCUR1 | mitochondrial calcium uniporter regulator 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT641242 | CENPN | centromere protein N | ![]() |
![]() |
2 | 2 | ||||||
MIRT642260 | ZNF677 | zinc finger protein 677 | ![]() |
![]() |
2 | 2 | ||||||
MIRT642954 | RELA | RELA proto-oncogene, NF-kB subunit | ![]() |
![]() |
2 | 2 | ||||||
MIRT644326 | IPP | intracisternal A particle-promoted polypeptide | ![]() |
![]() |
2 | 2 | ||||||
MIRT644632 | ICA1L | islet cell autoantigen 1 like | ![]() |
![]() |
2 | 2 | ||||||
MIRT645721 | POLR3A | RNA polymerase III subunit A | ![]() |
![]() |
2 | 2 | ||||||
MIRT647850 | LYPLA1 | lysophospholipase I | ![]() |
![]() |
2 | 2 | ||||||
MIRT649281 | NEK8 | NIMA related kinase 8 | ![]() |
![]() |
2 | 2 | ||||||
MIRT650038 | VHL | von Hippel-Lindau tumor suppressor | ![]() |
![]() |
2 | 2 | ||||||
MIRT650354 | RRP36 | ribosomal RNA processing 36 | ![]() |
![]() |
2 | 2 | ||||||
MIRT651144 | ZNF384 | zinc finger protein 384 | ![]() |
![]() |
2 | 2 | ||||||
MIRT651778 | UTP6 | UTP6, small subunit processome component | ![]() |
![]() |
2 | 2 | ||||||
MIRT652576 | TLCD2 | TLC domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT654621 | PTPRJ | protein tyrosine phosphatase, receptor type J | ![]() |
![]() |
2 | 2 | ||||||
MIRT656023 | MYO5A | myosin VA | ![]() |
![]() |
2 | 2 | ||||||
MIRT656105 | MSRB3 | methionine sulfoxide reductase B3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT657749 | GMEB1 | glucocorticoid modulatory element binding protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT657924 | GATSL2 | cytosolic arginine sensor for mTORC1 subunit 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT658848 | DUSP19 | dual specificity phosphatase 19 | ![]() |
![]() |
2 | 2 | ||||||
MIRT659100 | DENND6A | DENN domain containing 6A | ![]() |
![]() |
2 | 2 | ||||||
MIRT659153 | DCX | doublecortin | ![]() |
![]() |
2 | 2 | ||||||
MIRT660870 | ADRBK2 | G protein-coupled receptor kinase 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT661941 | FAHD1 | fumarylacetoacetate hydrolase domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT663577 | C10orf32 | BLOC-1 related complex subunit 7 | ![]() |
![]() |
2 | 2 | ||||||
MIRT664625 | WDPCP | WD repeat containing planar cell polarity effector | ![]() |
![]() |
2 | 4 | ||||||
MIRT666562 | RHOBTB3 | Rho related BTB domain containing 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT669992 | GPR156 | G protein-coupled receptor 156 | ![]() |
![]() |
2 | 4 | ||||||
MIRT670445 | RSBN1L | round spermatid basic protein 1 like | ![]() |
![]() |
2 | 2 | ||||||
MIRT670853 | IFNAR1 | interferon alpha and beta receptor subunit 1 | ![]() |
![]() |
2 | 4 | ||||||
MIRT671942 | SPPL3 | signal peptide peptidase like 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT674269 | LMOD3 | leiomodin 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT674424 | MIOX | myo-inositol oxygenase | ![]() |
![]() |
2 | 4 | ||||||
MIRT674982 | ATP5G1 | ATP synthase, H+ transporting, mitochondrial Fo complex subunit C1 (subunit 9) | ![]() |
![]() |
2 | 2 | ||||||
MIRT675038 | BACE2 | beta-site APP-cleaving enzyme 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT675309 | C2orf68 | chromosome 2 open reading frame 68 | ![]() |
![]() |
2 | 2 | ||||||
MIRT675641 | TTPAL | alpha tocopherol transfer protein like | ![]() |
![]() |
2 | 2 | ||||||
MIRT688688 | CPS1 | carbamoyl-phosphate synthase 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT689369 | ZNF101 | zinc finger protein 101 | ![]() |
![]() |
2 | 2 | ||||||
MIRT689605 | AKAP6 | A-kinase anchoring protein 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT691715 | LARS | leucyl-tRNA synthetase | ![]() |
![]() |
2 | 2 | ||||||
MIRT695473 | TRAT1 | T-cell receptor associated transmembrane adaptor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT695530 | MAP4K2 | mitogen-activated protein kinase kinase kinase kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT695878 | CACNG8 | calcium voltage-gated channel auxiliary subunit gamma 8 | ![]() |
![]() |
2 | 2 | ||||||
MIRT696586 | ORMDL2 | ORMDL sphingolipid biosynthesis regulator 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT703007 | HEATR5A | HEAT repeat containing 5A | ![]() |
![]() |
2 | 2 | ||||||
MIRT707942 | PHKA1 | phosphorylase kinase regulatory subunit alpha 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT709765 | GPR183 | G protein-coupled receptor 183 | ![]() |
![]() |
2 | 2 | ||||||
MIRT710332 | ZNF669 | zinc finger protein 669 | ![]() |
![]() |
2 | 2 | ||||||
MIRT713249 | ZFP30 | ZFP30 zinc finger protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT716613 | RBM18 | RNA binding motif protein 18 | ![]() |
![]() |
2 | 2 | ||||||
MIRT733414 | BAG2 | BCL2 associated athanogene 2 | ![]() |
![]() |
2 | 0 | ||||||
MIRT756135 | THSD7A | thrombospondin type 1 domain containing 7A | 3 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|